Ivan Grunberger, MD
Urology · Brooklyn, NYNPI 1528062247
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.3%. Reporting peaked in 2024 at $7,081 and has fallen 74.5% since, to $1,806 in 2025.
Across 118 payments — averaging $206.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gyrus ACMI, Inc.$5K
- Procept Biorobotics Corporation$5K
- EDAP Technomed Inc$3K
- Olympus America Inc.$3K
- Ambu A/s$3K
- Boston Scientific$2K
- plus $4K from 14 others
Across 31 payments — averaging $4325.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$95K
- Janssen Research & Development, LLC$16K
- Pfizer$16K
- Astellas Pharma Global Development$3K
- AbbVie$2K
- AstraZeneca$2K
What the payments were for
- Consulting fees$12,11650%
- Speaking & faculty fees$9354%
- Travel & lodging$5,32622%
- Food & beverage$5,70523%
- Education$3401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gyrus ACMI, Inc. | 10 | $4,946 |
| Procept Biorobotics Corporation | 24 | $4,706 |
| EDAP Technomed Inc | 19 | $3,244 |
| Olympus America Inc. | 2 | $3,150 |
| Ambu A/s | 2 | $3,012 |
| Boston Scientific | 14 | $1,647 |
| Janssen Global Services, LLC | 4 | $1,166 |
| Olympus Winter & Ibe GmbH | 1 | $900 |
| Astellas Pharma US Inc | 11 | $461 |
| Richard Wolf Medical Instruments Corp. | 3 | $332 |
| Ambu Inc. | 2 | $228 |
| AbbVie(2 entities) | 8 | $153 |
| Histosonics, Inc. | 1 | $130 |
| Pfizer | 4 | $87 |
| Myriad Genetic Laboratories, Inc. | 4 | $73 |
| Myovant Sciences Inc. | 3 | $61 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Merck | 2 | $35 |
| Coloplast | 1 | $30 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Soltive$4,647
- AQUABEAM SYSTEM$2,284
- AquaBeam Robotic System$1,749
- FOCAL ONE$1,564
- AMS$939
- Single Use Repositionable Clip$900
- GENERAL BPH$234
- GENERAL KIDNEY STONE DISEASE$149
- ACCUTRAC$124
- LithoVue$122
How this compares
$24,423 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 139 | $108,429 |
| GemtesaVibegron | 40 | $27,225 |
| Mirabegron ErMirabegron | 16 | $11,847 |
| Tamsulosin Hcl | 578 | $9,917 |
| Tadalafil | 34 | $9,584 |
| Silodosin | 67 | $8,474 |
| Solifenacin Succinate | 43 | $5,541 |
| Finasteride | 474 | $5,270 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 228 | $4,763 |
| Testosterone | 21 | $3,678 |
| Potassium Citrate ErPotassium Citrate | 30 | $3,480 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 23 | $3,225 |
| Estradiol | 11 | $2,346 |
| Tolterodine Tartrate | 45 | $1,989 |
| Methenamine Hippurate | 19 | $1,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $461 | $108,429139 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $43 | $27,22540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.
Other urology in Brooklyn
- William AtallahBrooklyn$191K
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.